# Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors

> **NCT06195384** · PHASE1 · RECRUITING · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** Neoantigen mRNA Vaccine

## Key facts

- **NCT ID:** NCT06195384
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-08
- **Primary completion:** 2027-12-30
- **Final completion:** 2037-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06195384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06195384, "Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06195384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*